Coherus Biosciences Inc (NASDAQ:CHRS) Receives $30.38 Average Price Target from Analysts

Share on StockTwits

Shares of Coherus Biosciences Inc (NASDAQ:CHRS) have received a consensus recommendation of “Buy” from the ten analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $30.29.

A number of equities research analysts have recently commented on the stock. ValuEngine cut shares of Coherus Biosciences from a “sell” rating to a “strong sell” rating in a report on Thursday, October 10th. TheStreet upgraded shares of Coherus Biosciences from a “d-” rating to a “c-” rating in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and issued a $29.00 price objective on shares of Coherus Biosciences in a research note on Monday, November 25th. Credit Suisse Group reissued a “buy” rating and issued a $36.00 price target on shares of Coherus Biosciences in a report on Friday, November 8th. Finally, Barclays set a $31.00 price target on shares of Coherus Biosciences and gave the company a “buy” rating in a report on Monday, August 12th.

Shares of NASDAQ:CHRS traded up $0.46 on Wednesday, reaching $18.45. The company’s stock had a trading volume of 120,310 shares, compared to its average volume of 1,106,165. The stock’s 50-day moving average is $18.35 and its two-hundred day moving average is $19.49. Coherus Biosciences has a 52-week low of $8.32 and a 52-week high of $23.91. The company has a debt-to-equity ratio of 3.37, a current ratio of 3.34 and a quick ratio of 3.25. The stock has a market capitalization of $1.26 billion, a P/E ratio of -5.73 and a beta of 2.88.

Coherus Biosciences (NASDAQ:CHRS) last announced its earnings results on Wednesday, November 6th. The biotechnology company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.36 by $0.27. The business had revenue of $111.68 million during the quarter, compared to analysts’ expectations of $93.58 million. Equities analysts forecast that Coherus Biosciences will post 1.36 earnings per share for the current fiscal year.

In related news, CFO Jean-Frederic Viret sold 3,159 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $20.44, for a total transaction of $64,569.96. Following the transaction, the chief financial officer now owns 11,672 shares in the company, valued at approximately $238,575.68. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Vincent R. Anicetti sold 2,500 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $20.03, for a total transaction of $50,075.00. Following the transaction, the chief operating officer now owns 21,810 shares in the company, valued at $436,854.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 847,217 shares of company stock worth $15,281,972. 18.20% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in CHRS. Cutler Group LP acquired a new position in Coherus Biosciences during the 3rd quarter valued at about $32,000. Tower Research Capital LLC TRC acquired a new position in Coherus Biosciences during the third quarter valued at approximately $52,000. Public Employees Retirement System of Ohio acquired a new position in Coherus Biosciences during the second quarter valued at approximately $75,000. Aperio Group LLC acquired a new position in Coherus Biosciences during the second quarter valued at approximately $80,000. Finally, Bank of Montreal Can acquired a new position in Coherus Biosciences during the second quarter valued at approximately $114,000. Institutional investors own 99.08% of the company’s stock.

About Coherus Biosciences

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Read More: The mechanics of the bid-ask spread in trading

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.